Search

Your search keyword '"Encephalopathy -- Drug therapy"' showing total 7 results
Start Over Descriptor "Encephalopathy -- Drug therapy" Topic orphan drugs
7 results on '"Encephalopathy -- Drug therapy"'

1. FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Protein binding, Business, News, opinion and commentary
Abstract

Wholly owned first-in-class program anticipated to enter clinical trials in first half of 2025 THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Capsida Biotherapeutics ('Capsida') today announced the U.S. Food [...]

Published
2024

3. ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, international, Law
Abstract

ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. This [...]

Published
2020

4. ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, Business, international
Abstract

RLS-0071 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that the [...]

Published
2020

5. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Insurance industry, Media executives, Newborn infants, General interest, News, opinion and commentary
Abstract

NORFOLK, Va: ReAlta Life Sciences, Inc. has issued the following news release: ReAlta Life Sciences, Inc., today announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation [...]

Published
2020

6. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Insurance industry, Media executives, Newborn infants, Diseases, Business, Business, international
Abstract

PIC1 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that U.S. [...]

Published
2020

7. ReAlta Life Sciences Granted EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, Business, international, Telecommunications industry
Abstract

ReAlta Life Sciences reported that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. According to a [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results